News
Public · Published
New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
Milestone Pharmaceuticals announced that CARDAMYST nasal spray converted approximately two-thirds of patients with recurrent symptomatic PSVT after prior catheter ablation to normal heart rhythm within 30 minutes. The result came from a subgroup analysis of the Phase 3 RAPID trial, and the company said it would be presented at the AHA Scientific Sessions on November 7.
Published:
Updated:
What happened
Milestone Pharmaceuticals announced that CARDAMYST nasal spray converted approximately two-thirds of patients with recurrent symptomatic PSVT after prior catheter ablation to normal heart rhythm within 30 minutes. The result came from a subgroup analysis of the Phase 3 RAPID trial, and the company said it would be presented at the AHA Scientific Sessions on November 7.
Confirmed
Global impact / market context
The findings point to a possible treatment option for adults whose rapid heart rhythm episodes return after ablation, potentially addressing a need for care outside emergency rooms. If the result supports broader use, CARDAMYST could contribute to Milestone’s sales, though the reported subgroup was small.
Analyst inference
CARDAMYST is already FDA-approved to convert acute symptomatic PSVT episodes to normal rhythm in adults, so this update concerns evidence in a specific group rather than a new approval. Investors may view the subgroup result as relevant to the medicine’s potential reach, but it does not establish commercial uptake or revenue.
Analyst inference
What to watch
- At the November 7 AHA presentation, watch for the subgroup’s size and full results; these details would help assess how much weight to place on the reported response. Analyst inference
- The article describes the group as small, so watch for further evidence in patients with prior ablation before treating this result as representative of routine care. Analyst inference
- Watch whether physicians use CARDAMYST for recurrent episodes after ablation; wider use could increase prescriptions and sales, while limited adoption would constrain that potential. Analyst inference